118
Views
9
CrossRef citations to date
0
Altmetric
Short Report

Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study

, , , , , , , , , , , , , , , & show all
Pages 1595-1601 | Published online: 25 Jul 2019

References

  • Yoo SH, Lee JH, Yoo KH, Jung K-S, Rhee CK. Different pattern of chronic obstructive pulmonary disease assessment test score between chronic bronchitis and non-chronic bronchitis patients. Tuberc Respir Dis (Seoul). 2018. doi:10.4046/trd.2017.0088
  • Spanish COPD Guidelines (GesEPOC) 2017; Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Pharmacological treatment of stable chronic obstructive pulmonary disease. Archivos De Bronconeumología. 2017;53(6):324–335. doi:10.1016/j.arbr.2017.03.01728477954
  • Tan WC. Trends in chronic obstructive pulmonary disease in the Asia-Pacific regions. Curr Opin Pulm Med. 2011;17(2):56–61. doi:10.1097/MCP.0b013e32834316cd21178626
  • Tan WC, Ng TP. COPD in Asia: where east meets west. Chest. 2008;133(2):517–527. doi:10.1378/chest.07-113118252918
  • Tan WC, Seale P, Ip M, et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology. 2009;14(1):90–97. doi:10.1111/j.1440-1843.2008.01415.x19144054
  • Rhee CK, Yoo KH, Lee JH, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis. 2013;17(1):67–75. doi:10.5588/ijtld.12.035123232006
  • Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med. 2014;2(10):823–860. doi:10.1016/S2213-2600(14)70168-725193349
  • Park J, Lim MN, Hong Y, Kim WJ. The influence of Asian dust, haze, mist, and fog on hospital visits for airway diseases. Tuberc Respir Dis (Seoul). 2015;78(4):326–335. doi:10.4046/trd.2015.78.4.32626508919
  • Loh LC. Chronic bronchitis is not necessary to define COPD. Respirol. 2011;16(3):574. doi:10.1111/j.1440-1843.2011.01931.x
  • Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur Respir J. 2017;49:5. doi:10.1183/13993003.01446-2016
  • Miravitlles M, Sliwinski P, Rhee CK, et al. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respir Med. 2018;136:8–14. doi:10.1016/j.rmed.2018.01.01929501251
  • Jose Soler-Cataluna J, Alcazar-Navarrete B, Miravitlles M. The concept of control in COPD: a new proposal for optimising therapy. Eur Respir J. 2014;44(4):1072–1075. doi:10.1183/09031936.0006441425063243
  • Soler-Cataluña JJ, Marzo M, Catalan P, et al. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719–3731. doi:10.2147/COPD.S17814930532528
  • Zhong N, Moon HS, Lee KH, et al. TIOtropium Safety and Performance In Respimat((R)) (TIOSPIR(TM)): analysis of Asian cohort of COPD patients. Respirology. 2016;21(8):1397–1403. doi:10.1111/resp.1285627490162
  • Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. Int J Chron Obstruct Pulmon Dis. 2018;13:2147–2156. doi:10.2147/COPD.S16994130034230
  • Wedzicha JA, Zhong N, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis. 2017;12:339–349. doi:10.2147/COPD.S12505828176893
  • World Health Organization. WHO report on the global tobacco epidemic 2017; 2017 Available from: https://www.who.int/tobacco/global_report/2017/en/.
  • Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112